Clinical Trial Update: A Study of Deucravacitinib to Treat LPP and FFA [Phase 2]

View source ↗

Summary

Phase 2 study of deucravacitinib for Lichen planopilaris and frontal fibrosing alopecia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontal Fibrosing Alopecia
• Lichen Planopilaris

Drugs mentioned

• Deucravacitinib (Sotyktu) (Deucravacitinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Lichen Planopilaris | Phase 2 | Status: COMPLETED | Results posted: 2025-06-08